Eric A. Hughes - 05 Mar 2026 Form 4 Insider Report for TEVA PHARMACEUTICAL INDUSTRIES LTD (TEVA)

Reporting relationship: Executive Vice President, Global R&D and Chief Medical Officer
Issuer ticker: TEVA
Reported as of: 05 Mar 2026
Net transaction value: -$301,895
SEC form: 4
Accepted by SEC: 09 Mar 2026, 16:14:56 UTC
Prior SEC filing: 06 Mar 2026
Next SEC filing: 12 Jun 2026
Source filing: View source filing
Reporting owner signature: /s/ Dov Bergwerk as attorney-in-fact for Eric A. Hughes

Key filing fact

Eric A. Hughes filed Form 4 for TEVA PHARMACEUTICAL INDUSTRIES LTD (TEVA) on 09 Mar 2026.

Key facts

This page summarizes Eric A. Hughes's Form 4 filing for TEVA PHARMACEUTICAL INDUSTRIES LTD (TEVA).
3 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 09 Mar 2026, 16:14.

Change

Previous filing in this sequence was filed on 06 Mar 2026.
Current net transaction value: -$301,895.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001938678 Primary reporting owner

Hughes Eric A

Relationship: Executive Vice President, Global R&D and Chief Medical Officer
Address: C/O TEVA PHARMACEUTICAL INDUSTRIES LTD., 124 DVORA HANEVI'A ST.,, TEL AVIV, ISRAEL
Signature: /s/ Dov Bergwerk as attorney-in-fact for Eric A. Hughes
Signature date: 09 Mar 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

TEVA transaction

Ordinary Shares

Options Exercise

Transaction value
Shares: +19,654
Change %: +20%
Price
Shares after: 117,244
Date: 05 Mar 2026
Ownership: Direct
Footnotes: F1, F2

TEVA transaction

Ordinary Shares

Sale

Transaction value: $301,895
Shares: -9,533
Change %: -8.1%
Price: $31.67
Shares after: 107,711
Date: 05 Mar 2026
Ownership: Direct
Footnotes: F1, F3, F4, F5

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

TEVA transaction Derivative

Restricted Share Units

Options Exercise

Transaction value
Shares: -19,654
Change %: -25%
Price: $0.000000^*
Shares after: 58,962
Date: 05 Mar 2026
Ownership: Direct
Underlying class: Ordinary Shares
Underlying amount: 19,654
Exercise price
Footnotes: F1, F2, F6

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Rule 10b5-1 trading plan

These transactions were reported as open-market trades under a Rule 10b5-1 plan. The plan lets an insider set trading instructions in advance, which can reduce the risk of trading while in possession of material nonpublic information.

Original filing language: transaction made pursuant to a contract, instruction, or written plan intended to satisfy Rule 10b5-1(c).

Explanation of responses 6 footnotes

Footnote F1

The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.

Footnote F2

Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share.

Footnote F3

The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 10, 2025.

Footnote F4

Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the restricted share units listed in Table II.

Footnote F5

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $31.26 to $32.34, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price.

Footnote F6

Restricted share units were granted on March 5, 2025, with 19,654 vested on March 5, 2026, and 19,654 vesting on each of March 5, 2027, March 5, 2028 and March 5, 2029.

SEC remarks

Executive Vice President, Global R&D and Chief Medical Officer